An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee

NCT00833911 | Completed Phase 3 Results

• 2 other identifiers: MDT3-004NCT00833911
• Study Type: interventional
• Target: 392
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to collect information regarding the long-term (6 and 12 months) safety of Tramadol HCl Once-A-Day(OAD) 300 mg.

Conditions

Osteoarthritis, Knee

Keywords

Moderate to severe symptomatic osteoarthritis of the knee

Outcome Measures

Primary Outcomes (1)

• Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation

  Spontaneous reports of adverse events were recorded for the entire study population, the 6-months safety population and the 12-months safety population

  6 months and 12 months

Study Arms (1)

Tramadol Contramid® OAD

EXPERIMENTAL

Drug: Tramadol Once A Day

Interventions

Tramadol Once A Day DRUG

Tramadol Contramid® OAD

Eligibility Criteria

• Age: 40 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis of the knee consistent with the American College of Rheumatology (ACR) Clinical Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):
• Current knee pain,
• Less than 30 minutes of morning stiffness with or without crepitus on active motion,
• Confirmation either by arthroscopy or radiologist's report (X-rays showing osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation}) within two years prior to entry into the study.
• Erythrocyte Sedimentation Rate (ESR) \< 40 mm/hour.
• Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale total score of \>= 150 mm at baseline. (5 questions/100 mm scale each with an averaged response of 30 mm or higher per question).
• Oral and written language comprehension at a level sufficient to comply with the protocol and complete study-related materials.
• The Patient has signed and dated the Research Ethics Board (REB) approved, written, informed consent prior to study participation.

You may not qualify if:

• Known rheumatoid arthritis or any other rheumatoid disease.
• Secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia; Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable arthritic disorders; or collagen gene mutations.
• Obesity Class II (Body Mass Index (BMI) \>= 35) (National Institutes of Health (NIH), 2000).
• Major illness requiring hospitalization during the 3 months before commencement of the screening period.
• Patients who are unwilling to stop taking pain medication other than the study medication (for arthritis or other types of pain) or are unwilling to stop taking other medications for the treatment of osteoarthritis (OA).
• Patients who have previously failed tramadol hydrochloride (HCl) therapy or those who discontinued tramadol HCl due to adverse events.
• Patients who are taking or within the last 3 weeks have taken the following medications: monoamine oxidase inhibitors; tricyclic antidepressants and other tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.
• Patients who are taking or have taken another investigational agent within the last 30 days.
• Patients with a history of seizure disorder other than Infantile Febrile Seizures.
• Patients who are opioid dependent.
• Patients with bowel disease causing malabsorption.
• Patients who are pregnant or lactating or patients of child-bearing potential who are unwilling to utilize a medically approved method of contraception during participation in this clinical trial.
• Patients with significant liver disease, defined as active hepatitis or elevated liver enzymes \>3 times the upper boundary of the normal range.
• Patients with significant renal disease, defined as creatinine clearance \<30 mL/min as estimated by the method of Levey et al., 1999.
• Current substance abuse or dependence, other than nicotine.

Sponsors & Collaborators

• Labopharm Inc.: lead

Related Publications (1)

• Mongin G. Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother. 2007 Dec;7(12):1775-84. doi: 10.1586/14737175.7.12.1775.

  PMID: 18052769 RESULT

Related Links

• Approved labelling

MeSH Terms

Conditions

Osteoarthritis, Knee

Condition Hierarchy (Ancestors)

Osteoarthritis; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Results Point of Contact

• Title: Director of Regulatory Affairs
• Organization: Labopharm Inc.

1 450 686 1017

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 29, 2009
• First Posted: February 2, 2009
• Study Start: April 1, 2003
• Primary Completion: July 1, 2004
• Study Completion: July 1, 2004
• Last Updated: April 30, 2012
• Results First Posted: June 2, 2009

Record last verified: 2012-04